arznei-telegramm® 04/2017 |
SPOT ON |
Amount of refund according to the AMNOG (Pharmaceutical Market Restructuring Act) – Higher Social Court questions calculation and cost effectiveness |
FOURIER study with evolocumab (REPATHA) – 2 million € per prevented event |
THERAPY FROM A CRITICAL VIEWPOINT |
Rivaroxaban for extended prophylaxis after thromboembolism? |
Are antibiotics unnecessary in uncomplicated diverticulitis? |
Bicalutamide (CASODEX 150 mg, generics) in PSA-recurrent prostate cancer after prostatectomy |
CURRENT ADR NETWORK REPORT | Anisocoria with escitalopram (CIPRALEX, generics) |
IN BRIEF |
Dabigatran (PRADAXA) versus warfarin (COUMADIN) for ablation in atrial fibrillation |
PRAC recommends suspension of marketing authorisations of four MRI contrast agents |
Finally – Servier ceases distribution of strontium ranelate (PROTELOS) |
FASTJECT lots recalled |
e a-t ON THE INTERNET |
France: 3rd and 4th generation contraceptives less and less prescribed |